| Keith E Macksoud, CRNA | |
|
1817 Old Louisquisset Pike, Lincoln, RI 02865-4516 | |
| (401) 727-2443 | |
| (401) 729-3476 |
| Full Name | Keith E Macksoud |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 38 Years |
| Location | 1817 Old Louisquisset Pike, Lincoln, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659346740 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RNA24719 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sturdy Memorial Hospital | Attleboro, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Anesthesia Pc | 9638255300 | 25 |
News Archive
Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company's development into a ‘specialty pharmaceutical' firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.
Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.
People in their 40's who drink alcohol regularly could be increasing their risk of mild cognitive impairment, a precursor to dementia and Alzheimer's. The claim is reported in the current issue of the British Medical Journal.
Nonin Medical, Inc., a leading innovator of physiological monitoring solutions and the inventor of fingertip pulse oximetry, will demonstrate the World's first Continua(TM) Certified Bluetooth® fingertip pulse oximeter, the Onyx® II, Model 9560, as part of the historic first end-to-end Continua(TM) connected health solution.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 6 days ago
| Entity Name | Narragansett Bay Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861445728 PECOS PAC ID: 5991774929 Enrollment ID: O20050714000216 |
News Archive
Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company's development into a ‘specialty pharmaceutical' firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.
Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.
People in their 40's who drink alcohol regularly could be increasing their risk of mild cognitive impairment, a precursor to dementia and Alzheimer's. The claim is reported in the current issue of the British Medical Journal.
Nonin Medical, Inc., a leading innovator of physiological monitoring solutions and the inventor of fingertip pulse oximetry, will demonstrate the World's first Continua(TM) Certified Bluetooth® fingertip pulse oximeter, the Onyx® II, Model 9560, as part of the historic first end-to-end Continua(TM) connected health solution.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 6 days ago
| Entity Name | Atlantic Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700061652 PECOS PAC ID: 9638255300 Enrollment ID: O20080320000208 |
News Archive
Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company's development into a ‘specialty pharmaceutical' firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.
Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.
People in their 40's who drink alcohol regularly could be increasing their risk of mild cognitive impairment, a precursor to dementia and Alzheimer's. The claim is reported in the current issue of the British Medical Journal.
Nonin Medical, Inc., a leading innovator of physiological monitoring solutions and the inventor of fingertip pulse oximetry, will demonstrate the World's first Continua(TM) Certified Bluetooth® fingertip pulse oximeter, the Onyx® II, Model 9560, as part of the historic first end-to-end Continua(TM) connected health solution.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 6 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043711914 PECOS PAC ID: 2860688728 Enrollment ID: O20180329001196 |
News Archive
Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company's development into a ‘specialty pharmaceutical' firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.
Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.
People in their 40's who drink alcohol regularly could be increasing their risk of mild cognitive impairment, a precursor to dementia and Alzheimer's. The claim is reported in the current issue of the British Medical Journal.
Nonin Medical, Inc., a leading innovator of physiological monitoring solutions and the inventor of fingertip pulse oximetry, will demonstrate the World's first Continua(TM) Certified Bluetooth® fingertip pulse oximeter, the Onyx® II, Model 9560, as part of the historic first end-to-end Continua(TM) connected health solution.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keith E Macksoud, CRNA 1817 Old Louisquisset Pike, Lincoln, RI 02865-4516 Ph: (401) 727-2443 | Keith E Macksoud, CRNA 1817 Old Louisquisset Pike, Lincoln, RI 02865-4516 Ph: (401) 727-2443 |
News Archive
Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company's development into a ‘specialty pharmaceutical' firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.
Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.
People in their 40's who drink alcohol regularly could be increasing their risk of mild cognitive impairment, a precursor to dementia and Alzheimer's. The claim is reported in the current issue of the British Medical Journal.
Nonin Medical, Inc., a leading innovator of physiological monitoring solutions and the inventor of fingertip pulse oximetry, will demonstrate the World's first Continua(TM) Certified Bluetooth® fingertip pulse oximeter, the Onyx® II, Model 9560, as part of the historic first end-to-end Continua(TM) connected health solution.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 6 days ago
Michael Paul Audette, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 17 E Butterfly Way, Lincoln, RI 02865 Phone: 401-723-3127 | |
Ms. Julie Ann Gemma, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Reverie Ln, Lincoln, RI 02865 Phone: 401-640-9480 |